Consumer Discretionary · Wholesale-Drugs, Proprietaries & Druggists' Sundries · NYSE · CIK 1140859 · FYE Sep 30 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $312.23Day −2.00%Mkt cap $60.7BP/E (FY) 39.2×1Y +7.8%Off 52W high −17.3%Vol (1Y) 31.3%
Daily closing price, split-adjusted to the current basis; 2.9y shown of 3,695 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Price impliesAGGRESSIVE · 14.8% growth |
| Short interest3.0% of sh out |
| Days to cover3.9d |
| 13F net flow (QoQ)−1.52% |
| Top-10 13F concentration47.6% |
| Next report (est.)2026-08-05 |
Fair value, confidence and the reverse-DCF grade are the MATERIALIZED daily snapshot (the same columns the screener serves), not a live model run. Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)39.2× |
| Sales (TTM)$328.68B |
| Earnings (TTM)$2.55B |
| ROE144.3% |
| Net margin0.5% |
| ROIC51.4% |
| YTD−7.2% |
| 1Y+7.8% |
| 3Y+71.4% |
| 5Y+168.3% |
| 10Y+405.8% |
| Since incept. (ann.)+26.3% |
Total return through 2026-07-30 · series begins 2011-07-11. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)31.3% |
| Ann. volatility (3Y)23.5% |
| Sharpe (1Y)0.44 |
| Sharpe (3Y)0.90 |
| Max drawdown (1Y)−32.4% |
| Max drawdown (3Y)−32.4% |
| Beta (3Y vs SPY)0.24 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 19.9M | $6.3B | 10.25% | −1.7% |
| VANGUARD CAPITAL MANAGEMENT LLC | 12.3M | $3.9B | 6.33% | new |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 9.6M | $3.0B | 4.93% | new |
| STATE STREET CORP | 9.2M | $2.9B | 4.72% | −1.2% |
| PRICE T ROWE ASSOCIATES INC /MD/ | 7.3M | $2.3B | 3.76% | +4.7% |
| FMR LLC | 6.7M | $2.1B | 3.44% | +22.5% |
| T. Rowe Price Investment Management, Inc. | 6.3M | $2.0B | 3.24% | −44.6% |
| GEODE CAPITAL MANAGEMENT, LLC | 5.6M | $1.7B | 2.86% | +2.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-06 | $8.40 | +128.3% | $78.36B | +3.8% |
| 2025-12-31 | 2026-02-04 | $2.87 | +14.8% | $85.93B | +5.5% |
| 2025-09-30 | 2025-11-05 | — | — | $83.73B | +5.9% |
| 2025-06-30 | 2025-08-06 | $3.52 | +45.5% | $80.66B | +8.7% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-05 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
| Total debt / EBITDA2.08× |
| EPS growth 3Y−0.3% |
| Sales growth 3Y10.4% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
